home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Webinar On FDA Inspections : Managing the Myth and the Reality

 
  October 27, 2014  
     
 


Compliance Trainings, Online
2014-11-18


FDA may inspect firms at a reasonable time, within reasonable limits and in a reasonable manner.  Whether or not an inspection appears reasonable depends on a person’s point of view. FDA investigators rely on well established procedures and techniques. In an FDA investigator’s mind, there really is no mystery about what happens during an inspection or why. The fact is though that many firms do not understand how an inspection is conducted and what follow-up regulatory action, if any, may be looming on the horizon.

Understanding the common elements of inspections can dispel some of the myths built up around them.  For FDA, inspections are a reality check, a snapshot, of a firm’s compliance with applicable FDA requirements and, to some degree, conformance with FDA guidance.

Why should you attend:

When FDA shows up at your front door to announce an inspection, what do you think is going to happen?  More importantly, what are you going do?

An ex-FDA investigator will conduct this webinar to share an “insider’s” perspective about inspections. You may find answers to the question, “What is he thinking?” when the investigator starts digging through the complaint files or starts reading memos on lunch room bulletin board.

Firms with an established FDA inspection protocol typically understand what happens during an inspection and why an inspection should be managed carefully. Many firms do not understand FDA inspections or may not have given them serious thought. That type of firm seemingly plans in a panic. 

How you manage an FDA inspection and the outcome of an inspection can have a material impact on the firm’s business, if not survival. The core direction of FDA inspections is to determine a firm’s level of compliance with FDA requirements and collect evidence to use against the firm for failing to comply with any regulatory requirement. The negative inspectional outcome can be costly in terms of money, lost business, consent decrees and the prosecution of the firm’s executives. Every FDA inspection concludes with a warning to that effect. How you manage an inspection can significantly affect the outcome. Prior knowledge about what happens during an inspection can serve you well and help you avoid trouble with FDA.

Areas Covered in the Session:

FDA’s overall inspectional program

FDA inspection preparation

FDA regulatory Compliance Programs

Investigations Operations Manual

Inspectional techniques

Who Will Benefit:

Note: All of the following areas are subject to FDA inspectional coverage

Senior Executives who are ultimately responsible for the firm

In-house legal counsel

Senior managers for Operations

Senior managers for Marketing

Regulatory Affairs Managers

Quality Assurance Managers

Manufacturing and Design Managers

Risk managers

FDA consultants

Price Tags:

Live

Single Live : For One Participant

$ 249

Corporate Live : For Max. 10 Participants

$ 899

Recording

Single REC : For One Participant - Unlimited Access for 6 Months

$ 299

For more information and enquiries contact us at

Compliance Trainings

5939 Candlebrook Ct, Mississauga, ON L5V 2V5, Canada 
Customer Support : #416-915-4458 
Email : support@compliancetrainings.com

For more information about this event please visit

 

https://compliancetrainings.com/SiteEngine/ProductDetailView.aspx?id=FDB1128

 
 
Organized by: Compliance Trainings
Invited Speakers:

Casper (Cap) Uldriks brings over 32 years of experience from the FDA. He specialized in the FDA's medical device program as a field investigator, served as a senior manager in the Office of Compliance and as an Associate Center Director for the Center for Devices and Radiological Health. He developed enforcement actions and participated in the implementation of new statutory requirements. He is recognized as an exceptional and energetic speaker. His comments are candid, straightforward and of practical value. He understands how FDA thinks, operates and where it is headed. Cap is the President of Encore Insight LLC, a consulting and training service for FDA law and operations.

 
Deadline for Abstracts: 2014-11-18
 
Registration:

https://compliancetrainings.com/siteengine/Login.aspx

E-mail: suzzane.d@compliancetrainings.com; uttam@compliancetrainings.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.